Tanaka et al. demonstrated reduced ERCC1 mRNA correlated with improved platinum-based chemoradiation therapy response in patients with ESCC, and suggested that histological assessment of tumor ERCC1 may predict individual responses to the adjuvant treatment paradigm [25]. This evidence concerns the gene ERCC1 and neoplasm.